Pregnancy and neonatal outcomes after prenatal exposure to dolutegravir: Data from a European cohort collaboration
Open Access
- 8 November 2026
- journal article
- Published by Wiley in HIV Medicine
Abstract
Objective: We aimed to assess ‘real‐world’ pregnancy and neonatal outcomes following prenatal dolutegravir (DTG) use in a European setting. Methods: We conducted a pooled analysis of individual‐patient data from seven observational studies. Pregnancies with DTG exposure any time from the periconception period (≤6 completed gestational weeks) were included. Congenital anomalies were assessed using criteria defined by the World Health Organization International Classification of Diseases: Tenth Revision (ICD‐10) and the European Network of population‐based registries for the epidemiological surveillance of congenital anomalies (EUROCAT). Results: Of 827 pregnancies, there were 764 live births, 37 miscarriages, 21 terminations and five stillbirths. No congenital anomalies were identified in the five stillborn infants. One termination was due to an identified congenital anomaly. Excluding four infants with chromosomal abnormalities, 34 live‐born infants had 37 anomalies. There were no central nervous system abnormalities. Live birth prevalence of congenital anomalies was 4.4% (95% CI 3.0, 6.1) according to ICD‐10; for infants with earliest DTG exposure in the periconception period, later in the first trimester and in the second/third trimester, prevalence was 4.7% (22/470), 2.6% (1/38) and 4.1% (11/265), respectively. Prevalence according to EUROCAT classification was 3.5% (95% CI 2.3, 5.0) overall. In live‐born singletons with earliest exposure at periconception/first trimester and second/third trimesters, 13.6% (66/485) and 13.7% (32/255) were preterm and 9.7% (46/474) and 6.5% (16/246) were small for gestational age, respectively. Conclusions: Our data on prenatal DTG use do not demonstrate increased risk of congenital anomalies compared to expected rates. Ongoing monitoring is needed to exclude association with rare anomalies.Keywords
Funding Information
- ViiV Healthcare
This publication has 30 references indexed in Scilit:
- Trends in termination of pregnancy for neural tube defects in England and Wales from 2007 to 2017: Observational prospective studyPrenatal Diagnosis, 2021
- Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysiseClinicalMedicine, 2020
- Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defectsJournal of the International AIDS Society, 2019
- Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational studyThe Lancet Global Health, 2018
- Safety and pharmacokinetics of dolutegravir in HIV-positive pregnant women: a systematic reviewJournal of Virus Eradication, 2018
- Comparative Safety of Antiretroviral Treatment Regimens in PregnancyJAMA Pediatrics, 2017
- Stillbirth: Case definition and guidelines for data collection, analysis, and presentation of maternal immunization safety dataVaccine, 2016
- International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st ProjectThe Lancet, 2014
- Pregnancy termination following prenatal diagnosis of anencephaly or spina bifida: A systematic review of the literatureBirth Defects Research Part A: Clinical and Molecular Teratology, 2012
- Teratogenicity risk of antiretroviral therapy in pregnancyCurrent HIV/AIDS Reports, 2007